Cargando…
Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
OBJECTIVE: To identify determinants for the discontinuation of non-ergoline dopamine agonist (DA) treatment in patients with Parkinson’s disease (PD) and to identify genetic determinants in genes encoding dopamine receptor (DR)D2 and DRD3 in a exploratory analysis. METHODS: Patients included were fi...
Autores principales: | Arbouw, Maurits E. L., Movig, Kris L. L., Egberts, Toine C. G., Poels, Petra J. E., van Vugt, Jeroen P. P., Wessels, Judith A. M., van der Straaten, R. J. H. M., Neef, Cees, Guchelaar, Henk-Jan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778789/ https://www.ncbi.nlm.nih.gov/pubmed/19669131 http://dx.doi.org/10.1007/s00228-009-0708-6 |
Ejemplares similares
-
Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case–control study
por: Arbouw, Maurits E. L., et al.
Publicado: (2011) -
Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs
por: Uijtendaal, Esther V., et al.
Publicado: (2011) -
Statin discontinuation in persons with and without Alzheimer’s disease
por: Vu, Mai, et al.
Publicado: (2022) -
Evaluation of patients’ experiences with antidepressants reported by means of a medicine reporting system
por: van Geffen, E. C. G., et al.
Publicado: (2007) -
Majority of drug-related problems identified during medication review are not associated with STOPP/START criteria
por: Verdoorn, Sanne, et al.
Publicado: (2015)